268: HER2/neu and Trastuzumab
Trastuzumab monoclonal antibodies targeting HER2 receptors are at the forefront of breast cancer treatment.
For more details, please refer the original article in PDB-101 of RCSB PDB.
Trastuzumab monoclonal antibodies targeting HER2 receptors are at the forefront of breast cancer treatment.
For more details, please refer the original article in PDB-101 of RCSB PDB.
This is an mirror page of the "Molecule of the Month" article provided in PDB-101 of the RCSB PDB. This article was released on April 2022. To reprinting and citation, please refer our terms and conditions page.
{
"header": {
"minimamHeightScale": 1.0,
"scalingAnimSec": 0.3
},
"src": {
"spacer": "/share/im/ui_spacer.png",
"dummy": "/share/im/ui_dummy.png"
},
"spacer": "/share/im/ui_spacer.png"
}